Drug survival in the treatment of generalized pustular psoriasis: A retrospective multicenter study

• DOI: 10.1111/dth.14814
• Publication Date: 2021-01-26T18:11:43Z
• Authors: Christian Kromer; Emilia Loewe; Marthe‐Lisa Schaa...; Andreas Pinter; Sascha Gerdes; Raphael Herr; Sietske Poortinga; Rotraut Moessner; Dagmar Wilsmann‐T...
• Keywords: Discontinuation; Ustekinumab; Acitretin

Generalized pustular psoriasis (GPP) is a rare, potentially life-threatening inflammatory skin disease. Our aim was to assess patient and disease characteristics analyze drug survival rates in the treatment of GPP real-life setting. In this retrospective study, 201 series 86 patients with treated at five University Medical Centers were analyzed. Overall, excellent response reached 41.3% all courses, partial 31.4%, nonresponse 27.3%. Biological significantly more effective than non-biological therapies (excellent response: 47.4% vs 35.9%; P = .02). median 14.0 months (biologicals: 36.0 nonbiologicals: 6.0 months; < .001). The crude probability highest for secukinumab (hazard ratio [HR] discontinuation compared acitretin: 0.22), followed by ixekizumab ustekinumab (HR: 0.38 each), adalimumab 0.59), etanercept 0.62), infliximab 0.69), cyclosporine 1.00), acitretin (reference HR), fumaric acid esters 1.06), methotrexate 1.26), apremilast 3.44); no guselkumab. results reveal high efficacy survival, particularly IL-17 IL-(12)/23 antagonists. Thus, these biologics may be considered early therapeutic algorithm GPP.